| Medicare advisory panel questions benefits of ESAs prior to transplantation |
|
| Fierce Pharma: A Medicare advisory panel isn't convinced that high-tech anemia drugs really benefit kidney patients awaiting transplants. In a meeting yesterday, the expert committee said there isn't enough evidence to justify using the drugs to raise patients' hemoglobin levels more than previously advised, Reuters reports. |